Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast and NB-UVB for Vitiligo
NCT03123016Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in Vitiligo, sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Change in proportion of responders to treatment at 32 weeks. Started Apr 2017; status: completed.
02
Drugs
apremilast
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT03123016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123016.